Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H2R5
UPID:
KLK15_HUMAN
Alternative names:
ACO protease
Alternative UPACC:
Q9H2R5; A0AUY8; Q15358; Q6ISI0; Q9H2R3; Q9H2R4; Q9H2R6; Q9HBG9
Background:
Kallikrein-15, also known as ACO protease, is a protease enzyme with a yet unidentified physiological substrate. Its alternative name and unique enzyme classification underscore its distinct role in biological processes.
Therapeutic significance:
Understanding the role of Kallikrein-15 could open doors to potential therapeutic strategies. Its unique enzymatic activity suggests a pivotal role in physiological processes, making it a target of interest in drug discovery.